Salona Global, which will soon be renamed Evome Medical Technologies, has announced the launch of a new portable medical device to treat patients with knee replacements and injuries.
The new product is called the Biodex SpaceTek Knee Device and will be exclusively distributed by the company’s subsidiary, Biodex Medical Systems.
Salona plans to submit an application seeking approval from the US Food and Drug Administration (FDA) for the system early next year.
The device was created in partnership with the National Aeronautics and Space Administration (Nasa) for use in outer space.
It is based on the technology available on the Biodex S4 isokinetic machine with dynamometers.
Biodex has developed the S4 product for the treatment of shoulders, knees and other joints.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The SpaceTek Knee Device is suitable for use in various locations based on the requirements of the clinic. Its entire dynamometer and electronics are packaged in a case that weighs under 70lb.
Salona Global has created four prototypes set to be released to the public next year.
These prototypes are being used by distributors from Japan, Europe and America to finalise marketing and sales plans for the same year.
Biodex and Nasa have signed an exclusive licence agreement under which Biodex will have exclusive US rights to the ‘Portable System and Apparatus for Dynamometry, Exercise and Rehabilitation’.
Nasa will receive a 2% royalty on net sales and the device must be sustainably manufactured in the US.
Salona Global CEO Mike Seckler said: “After a record revenue quarter finally generating positive adjusted EBITDA (as such term is defined in the company’s 15 November 2023 news release), we are moving boldly forward in debuting a product that we believe has great upside for Biodex.”